STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Clinical trials for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough bile duct cancers
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (FOLFOX) can shrink tumors or help people with advanced bile duct or gallbladder cancer live longer. About 66 adults whose cancer has a specific genetic change (MAPK pathway mutation) and has w…
Matched conditions: STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:24 UTC
-
New hope for bile duct cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or come back. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. The main goal is to see how many pa…
Matched conditions: STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 17, 2026 02:20 UTC
-
New combo therapy targets tough bile duct cancer
Disease control OngoingThis early-phase trial tests a new approach for people with advanced bile duct cancer that has spread. It combines a special type of radiation (given in fewer, stronger doses) with an immunotherapy drug called bintrafusp alfa, which helps the immune system fight cancer. The goal …
Matched conditions: STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests a new drug called pevonedistat, given alone or with standard chemotherapy (paclitaxel and carboplatin), in people with advanced bile duct cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors. About 40 adults who hav…
Matched conditions: STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 24, 2026 16:05 UTC